Boston Scientific Corporation

Company Overview

Business Model: Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The Company's mission is to transform lives through innovative medical solutions that improve patient health worldwide. For over 45 years, Boston Scientific has advanced less-invasive medicine by providing physicians with diagnostic and treatment alternatives to surgery for complex cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases and conditions, aiming to improve quality of life and reduce healthcare costs. Its core businesses are organized into two reportable segments: MedSurg and Cardiovascular.

Market Position: Boston Scientific is a medical technology leader, competing primarily on its ability to deliver differentiated clinical and economic outcomes through safe, effective, less-invasive, and cost-effective diagnostic and therapeutic procedures. The Company also competes on ease of use, comparative effectiveness, reliability, and physician familiarity. Key market leadership positions include its WATCHMAN™ Left Atrial Appendage Closure Devices, which are the leading devices in percutaneous Left Atrial Appendage Closure globally. The FARAPULSE™ Pulsed Field Ablation System has achieved rapid conversion from legacy treatment modalities and is now the predominant component of the Electrophysiology business unit's revenue.

Recent Strategic Developments:

• Acquisitions:
  • 2026 (Pending): Entered a definitive agreement to acquire 100% of Penumbra, Inc., a publicly traded medical technology company focused on thrombectomy products, for approximately $14.500 billion. The transaction is expected to close in 2026, funded by cash on hand, $11.000 billion in newly issued debt, and the remainder in common stock.
  • 2026 (Completed): Acquired 100% of Nalu Medical, Inc., a privately held medical technology company focused on chronic pain solutions, for approximately $517 million cash, net of cash acquired, on January 27, 2026.
  • 2025: Completed acquisitions of the remaining shares of Bolt Medical, Inc. (intravascular lithotripsy platform) and SoniVie Ltd. (TIVUS™ Intravascular Ultrasound System), 100% of Intera Oncology®, Inc. (hepatic artery infusion pump for liver cancer), Anrei Medical (HZ) Co., Ltd. (minimally invasive gastroenterology devices), and Cortex, Inc. (diagnostic mapping solution for atrial fibrillation), along with other businesses for an aggregate of $162 million.
  • 2024: Acquired 100% of Silk Road Medical, Inc. (carotid artery disease stroke prevention) for approximately $1.126 billion and Axonics, Inc. (urinary and bowel dysfunction devices) for approximately $3.411 billion.
• Product Approvals & Launches:
  • Received FDA approval in the U.S. and PMDA approval in Japan in Q2 and Q3 2025, respectively, to expand instructions for use labeling for the FARAPULSE™ Pulsed Field Ablation System to include treatment of drug refractory, symptomatic persistent atrial fibrillation.
  • Received CE mark for the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device in Q2 2025.
  • The FARAPULSE™ Pulsed Field Ablation System launched in the U.S. in early 2024.
• Product Discontinuation: Discontinued worldwide sales of the ACURATE Neo2™ and ACURATE Prime™ Aortic Valve Systems in Q2 2025 and will not pursue U.S. FDA approval for ACURATE.
• Restructuring: The global 2023 Restructuring Plan, initiated in Q1 2023 and substantially complete by the end of 2025, aimed to optimize the manufacturing and distribution network and functional capabilities. An expansion approved in July 2025 increased estimated total pre-tax charges to $700-$800 million, with expected gross annual pre-tax expense reductions of $350-$400 million, a substantial portion of which is planned for reinvestment in strategic growth initiatives.

Geographic Footprint: Boston Scientific markets its products and solutions in 127 countries worldwide. International net sales constituted 36% of global net sales in 2025. The Company's primary operational regions include the U.S., Western and Central Europe, Japan, Australia, New Zealand, and Canada. Emerging Markets, defined as all other countries, are a key component of the long-term growth strategy, with reported net sales growth primarily driven by China. The Company maintains 13 principal manufacturing facilities globally, including six in the U.S. and Puerto Rico, three in Ireland, two in Costa Rica, one in Malaysia, and one in China. Global headquarters are in Marlborough, Massachusetts, with regional headquarters in Singapore and Voisins-le-Bretonneux, France. Primary customer fulfillment centers are located in Massachusetts, the Netherlands, Malaysia, and Japan.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 69.0%
• Operating Margin: 18.0%
• Net Margin: 14.4%

Investment in Growth:

• R&D Expenditure: $2,052 million (10.2% of revenue)
• Capital Expenditures: $876 million
• Strategic Investments: Payments for acquisitions of businesses, net of cash acquired, totaled $1,593 million in 2025. Payments for investments and acquisitions of certain intangible assets totaled $254 million in 2025.

Business Segment Analysis

MedSurg

Financial Performance:

• Revenue: $6,824 million (+13.9% YoY reported, +6.7% YoY organic)
• Operating Margin: 33.2%
• Key Growth Drivers: In 2025, reported net sales growth was primarily driven by the Endoscopy business unit's biliary franchise, imaging systems, and endoluminal surgery franchises. The Urology business unit's growth was primarily driven by the acquisition of Axonics and its stone management franchise. The Neuromodulation business unit's growth was primarily driven by the Intracept™ Intraosseous Nerve Ablation System, and its spinal cord stimulation and deep brain stimulation franchises.

Product Portfolio:

• Endoscopy: Minimally invasive devices for diagnosing and treating gastrointestinal and pancreaticobiliary conditions and for supporting weight loss. Key products include hemostatic clips (Resolution 360™, MANTIS™ Clips), stent systems (WallFlex™ Biliary Stent Systems, AXIOS™ Stents and Electrocautery Enhanced Delivery Systems), single-use scopes (SpyGlass™, EXALT™ Model D Single-Use Duodenoscopes), endoluminal surgery products (OverStitch™ Endoscopic Suturing System, Orbera™ Intragastric Balloon System), and infection prevention products.
• Urology: Devices to treat various urological conditions for both male and female anatomies. Product offerings include a comprehensive line of stone management products (e.g., LithoVue™), laser systems (Lumenis Pulse™ Holmium Laser Systems with MOSES™ Technology, GreenLight XPS™ Laser System, Rezūm™ Systems), prosthetic urology products (AMS 700™ Penile Implant with the TENACIO™ Pump, AMS 800™ Artificial Urinary Sphincter), hydrogel systems (SpaceOAR™), and products to treat pelvic floor disorders (Axonics™ Sacral Neuromodulation System, Bulkamid™ Uretheral Bulking System).
• Neuromodulation: Devices to treat various neurological movement disorders and manage chronic pain. Product offerings include the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) System, Intracept™ Intraosseous Nerve Ablation System, G4™ Generator and consumable portfolio in Radiofrequency Ablation (RFA), and Vercise Genus™ Deep Brain Stimulation (DBS) System.

Market Dynamics: The MedSurg segment addresses a wide range of conditions, from gastrointestinal and urological disorders to chronic pain and movement disorders, with a focus on less-invasive and innovative technologies.

Cardiovascular

Financial Performance:

• Revenue: $13,250 million (+23.2% YoY reported, +20.8% YoY organic)
• Operating Margin: 32.5%
• Key Growth Drivers: In 2025, reported net sales growth was primarily driven by the Electrophysiology business unit, led by the FARAPULSE™ Pulsed Field Ablation System, continued market penetration of Left Atrial Appendage Closure (LAAC) procedures with WATCHMAN™ LAAC Devices, and the coronary therapies franchise, led by the AGENT™ Drug-Coated Balloon.

Product Portfolio:

• Interventional Cardiology and Vascular Therapies (ICVT): Technologies to diagnose and treat complex coronary, peripheral, and venous diseases. Portfolio includes intravascular imaging and multi-modality guidance systems (OptiCross™ IVUS Imaging Catheters, AVVIGO™+ Multi-Modality Guidance System), vessel preparation and plaque modification technologies (ROTAPRO™ Rotational Atherectomy Systems, WOLVERINE™ Coronary Cutting Balloon), coronary drug-eluting and drug-coated therapies (SYNERGY™ Everolimus-Eluting Stent Systems, AGENT™ Drug-Coated Balloon), peripheral vascular therapies (Eluvia™ Drug-Eluting Vascular Stent Systems, Ranger™ Drug-Coated Balloons), minimally invasive therapies for blood clots (AngioJet™ Thrombectomy Systems, EKOS™ Ultrasound Assisted Thrombolysis), and injectable treatments for venous reflux and varicose veins (Varithena™ Polidocanol Injectable Foam).
• Watchman: WATCHMAN™ Left Atrial Appendage Closure (LAAC) Devices, including the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device, designed to close the left atrial appendage in patients with non-valvular atrial fibrillation.
• Electrophysiology: Less-invasive medical technologies for diagnosing and treating heart rate and rhythm disorders. Product offerings include the FARAPULSE™ Pulsed Field Ablation (PFA) System, OPAL HDx™ Mapping System, VersaCross Connect™ Access Solutions portfolio, Polarsheath™ and Faradrive™ Steerable Sheath, and cyroablation and radiofrequency cardiac ablation systems.
• Cardiac Rhythm Management (CRM): Implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. Product offerings include implantable cardioverter defibrillators (RESONATE™), implantable cardiac resynchronization therapy defibrillators (HeartLogic™ Heart Failure (HF) Diagnostic, SmartCRT™ Technology), subcutaneous implantable cardiac defibrillators (EMBLEM™ MRI S-ICD System), pacemakers and implantable cardiac resynchronization therapy pacemakers (ACCOLADE™), remote patient management systems (LATITUDE™), and cardiac monitoring systems (BodyGuardian™ Remote Cardiac Monitoring Systems, LUX-Dx II+™ Insertable Cardiac Monitor System).
• Interventional Oncology and Embolization: Products to treat various forms of cancer. Portfolio includes technologies for liver cancer (TheraSphere™ Y-90, hepatic arterial infusion systems), cryoablation systems for kidney, bone, and lung cancers, and embolization devices (EMBOLD™ Detachable Coil System).

Market Dynamics: The Cardiovascular segment focuses on a broad spectrum of cardiac and vascular diseases, as well as interventional oncology, emphasizing innovative, less-invasive solutions and strong market penetration in key growth areas like PFA and LAAC.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Boston Scientific did not repurchase any shares of its common stock in 2025 or 2024. As of December 31, 2025, $1.000 billion remained available under the 2020 Share Repurchase Program.
• Dividend Payments: The Company did not pay a cash dividend on its common stock in 2025, 2024, or 2023 and currently does not intend to do so.
• Dividend Yield: Not applicable.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $1.965 billion
• Total Debt: $11.436 billion
• Net Cash Position: -$9.471 billion
• Credit Rating: Boston Scientific maintains investment grade credit ratings from Moody's Investor Service, Standard & Poor's Rating Service, and Fitch Ratings.
• Debt Maturity Profile:
  • 2026: $255 million
  • 2027: $1,058 million
  • 2028: $1,226 million
  • 2029: $1,154 million
  • 2030: $1,200 million
  • Thereafter: $6,451 million
  • Approximately 100% of total debt ($11.393 billion) is comprised of fixed-rate debt instruments.

Cash Flow Generation:

• Operating Cash Flow: $4,534 million (2025), up from $3,435 million (2024).
• Free Cash Flow: $3,658 million (2025), up from $2,645 million (2024).

Operational Excellence

Production & Service Model: Boston Scientific designs and manufactures its products in technology centers globally, utilizing both internal capabilities and third-party partners. The Company focuses on continuously improving supply chain effectiveness, strengthening manufacturing processes, and increasing operational efficiencies. Product quality is enhanced through process controls, validations, supplier and distribution controls, and team training.

Supply Chain Architecture: Key Suppliers & Partners: The majority of materials and components are sourced from third-party vendors. Certain critical items are purchased from single sources due to quality, expertise, cost, or regulatory considerations. Boston Scientific maintains an ongoing supplier resiliency program to identify and mitigate supply chain risks. Product sterilization is performed through a combination of internal resources and contract sterilizers.

Facility Network (as of December 31, 2025):

• Manufacturing: The Company operates 13 principal manufacturing facilities, including six in the U.S. and Puerto Rico, three in Ireland, two in Costa Rica, one in Malaysia, and one in China.
• Research & Development: R&D activities are conducted at facilities and centers of excellence worldwide, with collaborations extending to leading research institutions, universities, clinicians, and emerging market teams.
• Distribution: Primary customer fulfillment centers are located in Massachusetts, the Netherlands, Malaysia, and Japan.

Operational Metrics: Boston Scientific has obtained ISO14001:2015 Environmental Management Standard certification for 18 key locations and ISO50001:2018 Energy Management Standard certification for 14 key locations.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels: Boston Scientific primarily utilizes a direct sales force, which accounts for the majority of its net sales in countries where it operates directly. In other international markets, the Company leverages a network of independent distributors and dealers. Digital tools and technologies are continuously developed to support remote physician education, patient engagement, and sales force productivity.

Customer Portfolio: Enterprise Customers: The Company markets its products and solutions to a diverse customer base including hospitals, clinics, outpatient facilities, and medical offices. Large group purchasing organizations, hospital networks, and other buying groups represent a substantial portion of net sales. No single customer accounted for more than 10% of net sales in 2025, 2024, or 2023. The Company notes a trend of shifting procedure volumes in the U.S. towards non-hospital settings, such as ambulatory surgery centers and office-based labs, which may have more limited liquidity.

Geographic Revenue Distribution (2025):

• U.S.: 64.1% of total revenue ($12,864 million)
• Europe, Middle East and Africa: 17.2% of total revenue ($3,451 million)
• Asia-Pacific: 15.3% of total revenue ($3,080 million)
• Latin America and Canada: 3.4% of total revenue ($678 million)
• Emerging Markets: $2,985 million (14.9% of total revenue), representing a subset of the above international regions.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical device markets in which Boston Scientific operates are highly competitive, characterized by extensive research and development and rapid technological change. The industry faces pressures from managed care, economically motivated buyers, consolidation among healthcare providers, and increasing prevalence of regional and national tenders. Digital technologies, including artificial intelligence and machine learning, are increasingly important. Shifts in sites of care from inpatient to outpatient settings are impacting procedure volumes, product mix, and pricing. There is an increasing demand for robust health economic evidence and real-world outcomes data to support coverage and procurement.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Boston Scientific faces significant competition from large manufacturers with multiple lines of business, specialized medical device companies, low-cost manufacturers, and non-medical device companies (e.g., pharmaceutical, biotech, diagnostic solutions). Domestic medical device companies, particularly in countries like China, also pose competition.

Emerging Competitive Threats: New entrants, disruptive technologies, alternative solutions, and companies introducing new sales or distribution models, potentially leveraging genomic, robotic, navigation, and automation technologies, including AI.

Competitive Response Strategy: The Company's strategy includes continuously offering products with differentiated clinical and economic outcomes, developing or acquiring scientifically advanced technologies, attracting and retaining qualified personnel, protecting intellectual property, securing regulatory and reimbursement approvals, maintaining quality systems, and effectively marketing products to meet customer demand. It also involves developing new and enhanced digital capabilities.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: Boston Scientific faces risks from intense competition, rapid technological changes, and the emergence of low-cost alternatives. Declines in market size, average selling prices, or procedure volumes due to competitive activity, healthcare industry consolidation, government tenders, and economic pressures could adversely affect performance. Healthcare cost containment pressures, changes in government payment and delivery system reforms, and private payer policies may decrease demand or prices for products. Challenging domestic and international economic conditions, including inflation, interest rates, and geopolitical developments, could impact customer spending, supply chain stability, and operational costs. International operations are subject to risks from geopolitical and economic instability, foreign currency fluctuations, local regulatory changes, and trade protection measures.

Operational & Execution Risks

Supply Chain Vulnerabilities: The Company's global supply chain and manufacturing operations are vulnerable to interruptions from natural disasters, public health crises, geopolitical developments, equipment malfunctions, and facility damage. Disruptions in the supply of materials and components from third-party vendors, especially single-source items, or issues with product sterilization (e.g., due to evolving regulations on ethylene oxide or PFAS) could adversely affect operations. IT/OT System Disruptions: Reliance on information technology (IT) and operational technology (OT) systems makes the Company vulnerable to cyber-attacks, malicious intrusions, data breaches, and system failures. The integration of AI and legacy software components introduce additional risks. Such incidents could lead to operational interruptions, unauthorized data access, intellectual property theft, or harm to patients.

Financial & Regulatory Risks

Market & Financial Risks: Inability to manage debt levels or maintain investment grade credit ratings could increase borrowing costs and reduce liquidity. The Company is exposed to goodwill and other intangible asset impairment charges if future performance declines or key assumptions change. Regulatory & Compliance Risks: Boston Scientific is subject to extensive and dynamic medical device regulations globally (e.g., FDA, EU MDR), which can impede product approvals, increase costs, and lead to recalls or enforcement actions. Unexpected clinical trial results can adversely impact product approvals and market position. Failure to meet quality standards (e.g., QSR, ISO) can result in production delays, fines, and regulatory actions. The Company faces scrutiny and investigations from governmental authorities regarding marketing, business practices, and product quality, which could lead to civil/criminal proceedings, substantial fines, and administrative remedies. Intellectual property litigation is a significant risk, potentially limiting product sales or increasing costs. Product liability claims, particularly for implanted devices, pose an inherent risk of substantial damages.

Geopolitical & External Risks

Geopolitical Exposure: Ongoing global conflicts and tensions (e.g., Russia/Ukraine war, Taiwan strait, Middle East) can disrupt markets, supply chains, and operations. Proliferating sanctions and export restrictions create uncertainty in emerging markets. Shifts in trade policies, tariffs, and trade protection measures could materially impact financial condition and operations.

Innovation & Technology Leadership

Research & Development Focus: Boston Scientific's R&D efforts are largely directed towards developing next-generation and novel technology offerings across all divisions, aiming to expand current markets and enter high-growth adjacencies. A key focus is on digital tools and technologies to enhance remote physician education, patient engagement, and sales force productivity.

Core Technology Areas: The Company invests in areas such as Pulsed Field Ablation (PFA) for cardiac rhythm disorders, Left Atrial Appendage Closure (LAAC) devices, intravascular lithotripsy, intravascular ultrasound for hypertensive disorders, hepatic artery infusion therapy for cancer, and diagnostic mapping solutions for atrial fibrillation.

Innovation Pipeline: Significant investment in R&D, clinical trials, and regulatory approvals supports a robust innovation pipeline. Recent successes include the rapid adoption of the FARAPULSE™ PFA System and the CE mark for the WATCHMAN FLX™ Pro LAAC Device, which offers improved visualization and broader anatomical treatment.

Intellectual Property Portfolio: Boston Scientific relies on a combination of patents, trademarks, trade secrets, and other intellectual property rights to protect its proprietary technologies. It actively files patent applications globally and holds numerous patents and licenses to third-party technologies. Non-disclosure and non-competition agreements are used to safeguard trade secrets.

Technology Partnerships: The Company collaborates with leading research institutions, universities, and clinicians worldwide for product development, evaluation, and clinical testing. It is also expanding R&D collaborations into emerging market countries to address global and local market requirements more cost-effectively.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: Boston Scientific emphasizes robust succession planning and ongoing employee growth and development initiatives to ensure leadership continuity.

Board Composition: The Board of Directors oversees an enterprise-wide approach to risk management, including cybersecurity risks. The Executive Committee and Board also oversee policies and strategies related to diversity and inclusion, employee engagement, talent recruitment and development, pay equity, and company culture. The Board receives regular updates on cybersecurity and the enterprise risk management program.

Human Capital Strategy

Workforce Composition: As of December 31, 2025, Boston Scientific had approximately 59,000 employees, with about 60% located outside the U.S. The Company views its collective talent and shared corporate culture as a competitive advantage.

Talent Management: Acquisition & Retention: The Company strives to attract, develop, and retain talent by fostering a diverse, equitable, and inclusive workplace, offering competitive pay and benefits, providing flexible work conditions, and cultivating a culture that prioritizes employee health, safety, and well-being. Diversity & Development: Boston Scientific focuses on workforce development through initiatives aimed at building a talent pipeline and fostering an inclusive workplace. Its ten Employee Resource Groups (ERGs) are central to its inclusion strategy, providing forums for learning and leadership development. The Company also integrates inclusive practices into its supplier selection process. Development programs include professional and technical courses, on-the-job training, mentoring, and leadership development.

Culture & Engagement: Boston Scientific offers holistic programs focusing on physical, financial, and emotional well-being. It seeks ongoing employee feedback through communication and periodic engagement surveys to understand and improve the employee experience.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: Boston Scientific manages its environmental impacts through enterprise-wide policies and operational controls for energy use, greenhouse gas emissions, and waste management. Its approach includes reducing energy consumption, converting to renewable energy where feasible, and utilizing carbon offsets. The Company holds ISO14001:2015 Environmental Management Standard certification for 18 key locations and ISO50001:2018 Energy Management Standard certification for 14 key locations. Supply Chain Sustainability: The Company engages suppliers on ESG requirements and supplier diversity programs, and practices responsible sourcing, including conflict minerals compliance.

Social Impact Initiatives: Boston Scientific supports employee engagement through volunteerism and giving, including an Employee Matching Gifts program. It collaborates with nonprofit organizations on health education, workforce development, and reducing health disparities. The "Close the Gap" initiative focuses on raising healthcare provider awareness about health disparities and addressing barriers to care for underserved communities. The Company also supports STEM education initiatives for underrepresented students.

Business Cyclicality & Seasonality

Demand Patterns: While Boston Scientific's consolidated net sales do not exhibit a significant degree of seasonality, customer purchases of its medical devices have historically been lower in the first and third quarters of the year. Demand is influenced by various factors including product launches, acquisitions, regulatory and reimbursement approvals, and holiday schedules.

Planning & Forecasting: Not explicitly detailed in the provided filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: Boston Scientific's medical devices are subject to extensive regulation by numerous global bodies, including the FDA in the U.S., the European Medicines Agency (EMA) in Europe, and comparable agencies in China (NMPA) and Japan (MHLW and PMDA). This includes laws governing development, testing, manufacturing, labeling, marketing, and distribution. In the U.S., products require 510(k) clearance or PMA approval. In the EU, a CE Mark is required, with compliance to the Medical Device Regulation (MDR) effective May 2021, and transitional periods extended to 2027 for high-risk devices and 2028 for lower-risk devices. Many other countries impose local registration requirements and require regular product approval renewals. The Company's quality system is designed to satisfy international quality system regulations, including FDA's Quality System Regulation and ISO 13485, with all medical device manufacturing and key distribution sites certified under ISO 13485. Trade & Export Controls: The Company is governed by federal, state, local, and international laws related to trade and export controls, including U.S. and foreign import/export controls, trade protection, embargo measures, and customs laws. International sales of devices not approved by the FDA for U.S. use are subject to FDA export requirements.

Legal Proceedings: Boston Scientific is involved in various legal and regulatory proceedings, including intellectual property, product liability, securities, commercial claims, employment, environmental matters, and governmental inquiries. In 2025, the Company recorded $194 million in litigation-related net charges for the resolution of a legacy IP-related matter. Product liability cases related to transvaginal surgical mesh products are ongoing, with an accrual established for remaining claims and defense costs. Patent litigation includes a lawsuit by The Board of Regents, University of Texas System and TissueGen. Inc. concerning the Synergy™ Stent System, which resulted in a $42 million jury award against the Company in January 2023, with appeals filed by both parties. An arbitration dispute with Al Mann Foundation, assumed with the Axonics acquisition, was resolved through a confidential settlement in December 2025.

Tax Strategy & Considerations

Tax Profile: Boston Scientific's reported tax rate was 14.6% in 2025, with a rate from continuing operations of 18.9%. The Company's tax profile is influenced by earnings in foreign jurisdictions with differing tax rates. Geographic Tax Planning: Manufacturing facilities in Costa Rica operate under a Free Trade Zone regime, and the Company benefits from tax holidays and incentive grants in other countries, set to expire between 2028 and 2034. The Costa Rican Free Trade Zone regime has been extended through 2033. These tax reductions favorably impacted net income attributable to Boston Scientific common stockholders by $540 million in 2025. Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), signed in July 2025, introduced changes to corporate income taxes, including immediate expensing of U.S. R&D expenditures and modifications to international operations taxation, with an immaterial impact on the 2025 tax rate and a similar impact expected for 2026. Many countries adopted the OECD's Pillar Two global minimum effective tax rate of 15% in 2024. While the U.S. has not enacted it, new OECD Administrative Guidance in January 2026 introduced safe harbors that could exempt U.S.-based multinationals from certain Pillar Two elements starting 2026, if legislated domestically.

Insurance & Risk Transfer

Risk Management Framework: Boston Scientific manages market risks from currency exchange rates and interest rates through a risk management program that includes derivative financial instruments. Counterparty risk on derivatives is managed by diversifying with major financial institutions and actively monitoring positions. Insurance Coverage: The Company maintains an insurance policy providing limited coverage against securities claims. It is substantially self-insured for product liability and environmental claims and fully self-insured for intellectual property infringement claims. Risk Transfer Mechanisms: Derivative financial instruments, primarily forward currency contracts, are used to hedge currency risk. The Company had no interest rate derivative instruments outstanding as of December 31, 2025, with approximately 100% of its total debt at fixed interest rates.